Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats

Drugs under Experimental and Clinical Research

Volumn 31, Issue 4, 2005, Pages 155-159

  Nakamura, K ^a   Yamagishi, Sho Ichi ^a   Matsui, T ^a   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; FRUCTOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ACARBOSE; ALPHA-GLUCOSIDASES; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; ENZYME INHIBITORS; FRUCTOSE; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 26244468723     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fernandes-Real J.M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endoc. Rev., 24, 278, 2003.
2. Fong T.M. Targeting metabolic syndrome. Expert. Opin. Investig. Drugs, 13, 1203, 2004.
3. Hsueh W.A., Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am. J, Cardiol., 92, 10J, 2003.
4. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol., 93, 136, 2004.
5. Heine R.J., Dekker J.M. Beyond postprandial hyperglycaemia: Metabolic factors associated with cardiovascular disease. Diabetologia, 45, 461, 2002.
6. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 22, 920, 1999.
7. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet, 354, 617, 1999.
8. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia, 39, 1577, 1996.
9. Breuer H.W.M. Reviews of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int. J. Clin. Pharm. Therap., 41, 421, 2003.
10. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet, 359, 2072, 2002.
11. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA, 290, 486, 2003.
12. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke, 35, 1073, 2004.
13. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur. Heart J., 25, 10, 2004.
14. Hwang I.S., Ho H., Hoffman B.B. Reaven G.M. Fructose-induced insulin resistance and hypertension in rats. Hypertension, 10, 512, 1987.
15. Elliott S.S., Keim N.L., Stern J.S., Teff K., Havel P.J. Fructose, weight gain, and the insulin resistance syndrome. Am. J. Clin. Nutr., 76, 911, 2002.
16. Yamagishi S., Nakamura K., Imaizumi T. Adavanced glycation end products (AGEs) and diabetic vascular complications. Curr. Diabetes Rev., 1, 93, 2005.
17. Furukawa S., Fujita T., Shimabukuro M., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 114, 1752, 2004.
18. Ceriello A., Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 24, 816, 2004.